BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...
Drug
CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...
Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program
Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...
Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...
Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...
GenScript Biotech’s CAR-T Therapy Carvykti Reports USD 117 Million in Sales
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation...
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter...
Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...
Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study
Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...
Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy
A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...
Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China
The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...
HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...
Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial...
Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...
Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China
Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced...
Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...
Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...